{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:29:58Z","timestamp":1764883798884,"version":"3.46.0"},"reference-count":33,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,22]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Depression and depressive symptoms are common in the elderly population and contribute to a lower quality of life. One change that is common in depression is the disruption of circadian cycles, which are regulated by melatonin and other neurotransmitters. Oral melatonin and melatonin agonists are well tolerated, being the main clinical indication of insomnia. A melatonin agonist is approved as an antidepressant. Thus, the objective of the systematic review will be to provide an up-to-date synthesis of the findings of randomised controlled trials that used melatonin or melatonin agonists as a therapeutic intervention in elderly people with depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This systematic review protocol was registered with PROSPERO under the number CRD42023391092. We will conduct a systematic review and possible meta-analysis of the efficacy of melatonin and melatonin agonists in the treatment of depression. Comparators will include placebo and active treatments (eg, antidepressants). We will search international electronic databases, including the Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials), EMBASE, PUBMED\/MEDLINE and SciELO for published randomised control trial studies, and ongoing work and trials in progress by searching key internet-based relevant databases from inception to April 2025. There will be no restrictions on the language or geography of publication. The Cochrane\u2019s risk of bias tool for randomised trials (RoB2) will be used to appraise the risk of bias, and GRADE tools will be used to evaluate the overall quality of the included studies. A descriptive summary with data tables will be constructed, and if adequate, we will perform a meta-analysis. A random-effects model will be used when substantial heterogeneity is present, otherwise, a fixed-effects model will be considered (\n                      <jats:italic>I\u00b2&lt;50%<\/jats:italic>\n                      ). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist will be followed for reporting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Since this systematic review will be based only on published and retrievable literature, no ethics approval will be required. A multidisciplinary team has been assembled for this systematic review and will participate in relevant dissemination activities, namely reports, publications and presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42023391092.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-105882","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:46:40Z","timestamp":1762264000000},"page":"e105882","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Melatonin and melatonin agonists as antidepressants in the elderly: protocol for a systematic review and meta-analysis of randomised control trials"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0193-8709","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Cardoso","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences, University of Beira Interior, Covilh\u00e3, Portugal"},{"name":"Santa Casa da Miseric\u00f3rdia de Lisboa, Lisbon, Portugal"},{"name":"RISE Health - Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-2407","authenticated-orcid":false,"given":"Nuno","family":"Pinto","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Beira Interior, Covilh\u00e3, Portugal"},{"name":"RISE Health - Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal"},{"name":"GRUBI, University of Beira Interior Systematic Reviews Group, Covilh\u00e3, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-9565","authenticated-orcid":false,"given":"Tiago","family":"Maricoto","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Beira Interior, Covilh\u00e3, Portugal"},{"name":"RISE Health - Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal"},{"name":"GRUBI, University of Beira Interior Systematic Reviews Group, Covilh\u00e3, Portugal"},{"name":"Beira Ria Family Health Unit, Unidade Local de Sa\u00fade da Regi\u00e3o de Aveiro, \u00cdlhavo, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0653-3428","authenticated-orcid":false,"given":"Assun\u00e7\u00e3o Vaz","family":"Patto","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Beira Interior, Covilh\u00e3, Portugal"},{"name":"RISE Health - Faculty of Health Sciences, University of Beira Interior, Covilha, Portugal"},{"name":"GRUBI, University of Beira Interior Systematic Reviews Group, Covilh\u00e3, Portugal"}]}],"member":"239","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2025120413254540000_15.11.e105882.1","doi-asserted-by":"crossref","unstructured":"Lim GY , Tam WW , Lu Y , et al . Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep 2018;8. doi:10.1038\/s41598-018-21243-x","DOI":"10.1038\/s41598-018-21243-x"},{"key":"2025120413254540000_15.11.e105882.2","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3346\/jkms.2017.32.11.1861","article-title":"Prevalence and associated factors of depression in general population of korea: results from the Korea National Health and Nutrition Examination Survey, 2014","volume":"32","author":"Shin","year":"2017","journal-title":"J Korean Med Sci"},{"key":"2025120413254540000_15.11.e105882.3","doi-asserted-by":"crossref","unstructured":"Rodda J , Walker Z , Carter J . Depression in older adults. BMJ 2011;343. doi:10.1136\/bmj.d5219","DOI":"10.1136\/bmj.d5219"},{"key":"2025120413254540000_15.11.e105882.4","doi-asserted-by":"crossref","first-page":"103417","DOI":"10.1016\/j.ajp.2022.103417","article-title":"Global prevalence of depression in older adults: a systematic review and meta-analysis of epidemiological surveys","volume":"80","author":"Cai","year":"2023","journal-title":"Asian J Psychiatr"},{"key":"2025120413254540000_15.11.e105882.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.10.041"},{"key":"2025120413254540000_15.11.e105882.6","doi-asserted-by":"crossref","first-page":"113239","DOI":"10.1016\/j.psychres.2020.113239","article-title":"Clarifying the role of sleep in depression: a narrative review","volume":"291","author":"Pandi-Perumal","year":"2020","journal-title":"Psychiatry Res"},{"key":"2025120413254540000_15.11.e105882.7","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.euroneuro.2014.08.008","article-title":"The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis","volume":"24","author":"Hansen","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"2025120413254540000_15.11.e105882.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2006.05322.x"},{"key":"2025120413254540000_15.11.e105882.9","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1007\/s11064-022-03646-5","article-title":"Melatonergic Receptors (Mt1\/Mt2) as a potential additional target of novel drugs for depression","volume":"47","author":"Boiko","year":"2022","journal-title":"Neurochem Res"},{"key":"2025120413254540000_15.11.e105882.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61415-9"},{"key":"2025120413254540000_15.11.e105882.11","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1111\/bph.14197","article-title":"Circadian modulation of neuroplasticity by melatonin: a target in the treatment of depression","volume":"175","author":"Vald\u00e9s-Tovar","year":"2018","journal-title":"Br J Pharmacol"},{"key":"2025120413254540000_15.11.e105882.12","doi-asserted-by":"crossref","unstructured":"Guaiana G , Gupta S , Chiodo D , et al . Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev 2013;2013. doi:10.1002\/14651858.CD008851.pub2","DOI":"10.1002\/14651858.CD008851.pub2"},{"key":"2025120413254540000_15.11.e105882.13","doi-asserted-by":"crossref","unstructured":"Nussbaumer-Streit B , Thaler K , Chapman A , et al . Second-generation antidepressants for treatment of seasonal affective disorder. Cochrane Database Syst Rev 2021;3. doi:10.1002\/14651858.CD008591.pub3","DOI":"10.1002\/14651858.CD008591.pub3"},{"key":"2025120413254540000_15.11.e105882.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2021.113724"},{"key":"2025120413254540000_15.11.e105882.15","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.828690"},{"key":"2025120413254540000_15.11.e105882.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"2025120413254540000_15.11.e105882.17","doi-asserted-by":"crossref","unstructured":"Ulley J , Harrop D , Ali A , et al . Deprescribing interventions and their impact on medication adherence in community-dwelling older adults with polypharmacy: a systematic review. BMC Geriatr 2019;19. doi:10.1186\/s12877-019-1031-4","DOI":"10.1186\/s12877-019-1031-4"},{"key":"2025120413254540000_15.11.e105882.18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/acps.12755","article-title":"Melatonin as a treatment for mood disorders: a systematic review","volume":"136","author":"De Crescenzo","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"2025120413254540000_15.11.e105882.19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.pop.2017.04.007","article-title":"Depression in Older Adults A Treatable Medical Condition","volume":"44","author":"Casey","year":"2017","journal-title":"Prim Care: Clin Off Pr"},{"key":"2025120413254540000_15.11.e105882.20","unstructured":"Higgins JPT , Thomas J , Chandler J . Cochrane Handbook for Systematic Reviews of Interventions. Published Online First: 2023."},{"key":"2025120413254540000_15.11.e105882.21","doi-asserted-by":"crossref","unstructured":"Page MJ , McKenzie JE , Bossuyt PM , et al . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372. doi:10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"2025120413254540000_15.11.e105882.22","unstructured":"Rayyan: a systematic reviews web app for exploring and filtering searches for eligible studies for cochrane reviews. n.d."},{"key":"2025120413254540000_15.11.e105882.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2025120413254540000_15.11.e105882.24","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"2025120413254540000_15.11.e105882.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01866-8"},{"key":"2025120413254540000_15.11.e105882.26","doi-asserted-by":"crossref","unstructured":"Sterne JAC , Savovi\u0107 J , Page MJ , et al . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366. doi:10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"2025120413254540000_15.11.e105882.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"2025120413254540000_15.11.e105882.28","unstructured":"Review Manager Web."},{"key":"2025120413254540000_15.11.e105882.29","unstructured":"Team RC . R: A Language and Environment for Statistical Computing. 2024."},{"key":"2025120413254540000_15.11.e105882.30","unstructured":"Team Rs . n.d. RStudio: Integrated Development for R. Published Online First:2024."},{"key":"2025120413254540000_15.11.e105882.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025120413254540000_15.11.e105882.32","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"2025120413254540000_15.11.e105882.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-105882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:26:32Z","timestamp":1764883592000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-105882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-105882"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-105882","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}